Wynn Macau has awarded share-based incentives to four employees under its Employee Ownership Scheme, reinforcing its strategy of aligning employee interests with the company's long-term growth and shareholder value.
The company announced that it granted awards covering a total of 886,547 ordinary shares, representing around 0.02% of its issued share capital. The awards were granted at no cost to the recipients, based on the company's closing share price of HK$5.07 (US$0.65) on the grant date.
The awards carry staggered vesting schedules designed to promote long-term commitment. Two employees will receive one-third of their awards annually between 2027 and 2029, while another employee's award will vest in four equal installments from 2027 through 2030. The fourth employee will receive the award in two equal portions in 2027 and 2028.
Although the first vesting dates for each award occur within 12 months of the grant date, Wynn Macau said the overall vesting structure extends over multiple years. The board and the remuneration committee believe the arrangement remains commercially competitive while ensuring employees remain focused on the company's long-term development.
The awards are not tied to specific performance targets. However, they remain subject to forfeiture if an employee resigns, is dismissed for misconduct, breaches company policies, or violates applicable laws or employment agreements before the awards vest.
Wynn Macau also confirmed that it has not provided any financial assistance to employees for acquiring the shares under the scheme.
The Employee Ownership Scheme was established to strengthen the alignment between employees and shareholders, attract and retain talent, and recognize contributions to the group's long-term profitability. Following the latest grant, more than 481.1 million shares remain available for future awards under the scheme mandate, with an additional 10.4 million shares reserved under the service provider sublimit.
The awards were made under Wynn Macau's Employee Ownership Scheme, which was introduced in 2023
